Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Japan Pharma Market Likely to Reach 9.7 Trillion Yen in 2022: Fuji Keizai
November 18, 2015
- Generic Makers’ Earnings Show Unabated Momentum 1 Year after Medical Fee Reform: Tally
November 17, 2015
- Otsuka Hopes Abilify Maintena Grabs 30% Share in Global Atypical Antipsychotic Market in 2018
November 17, 2015
- AZ Eyes Low Single-Digit Growth over Coming Years in Japan: Pres. Baertschi
November 16, 2015
- Bayer Yakuhin Now Marketing Authorization Holder for Claritin
November 16, 2015
- Taiho Files for Japan Approval of Allergy Drug Bilastine
November 16, 2015
- Senju, Gene Techno to Form Capital Tie-Up for Biosimilar Development in Ophthalmology
November 16, 2015
- NHI Prices of Plavix Generics “Actually 43% Rather than 50% Price of Original Product”: Sawai Pharmaceutical President
November 16, 2015
- Japanese Makers Earn Overseas in 1st Half, Japan Sales Up Only Slightly: Tally
November 13, 2015
- OrphanPacific Aims to Achieve Black Ink in 2017
November 13, 2015
- Astellas to Transfer Global Dermatology Portfolio to LEO Pharma
November 12, 2015
- Sovaldi Best-Selling Drug in July-September after May Launch: IMS
November 11, 2015
- Astellas to Acquire US Biotech Ocata Therapeutics for US$379 Million
November 11, 2015
- Top 4 Wholesalers See 7% Sales Rise on Hep C Drugs, but Paltry 0.82% in Operating Margin
November 11, 2015
- Chugai, Kowa Expand Licensing Deal for Deberza
November 11, 2015
- Ethical Dug Sales Climb 7.8% in September: Crecon Report
November 11, 2015
- Fujifilm’s AML Drug Candidate to Enter PI in US
November 11, 2015
- Shionogi, GSK to Independently Develop Jointly Researched Antibiotics
November 10, 2015
- Jardiance Jumps into Top 20 Ranking on Physicians’ Recollection: Anterio
November 10, 2015
- AZ’s Lung Cancer Treatment Gets Priority Review Status in Japan
November 9, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…